Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Marcellin

Showing results (161-170 of 212) with videos related to

Pageof 22
Sort By:
Journal of Viral Hepatitis|September 24, 2016
No detectable resistance to tenofovir disoproxil fumarate in HBeAg+ and HBeAg- patients with chronic hepatitis B after 8 years of treatmentY Liu, A C Corsa, M Buti, et al.
Gut|September 27, 2007
Liver gene expression signature to predict response to pegylated interferon plus ribavirin combination therapy in patients with chronic hepatitis CT Asselah, I Bieche, S Narguet, et al.
Clinical and Experimental Immunology|November 1, 1995
CD4+/CD8+ ratio of liver-derived lymphocytes is related to viraemia and not to hepatitis C virus genotypes in chronic hepatitis CB N Pham, M Martinot-Peignoux, J F Mosnier, et al.
Lancet (London, England)|November 10, 1998
Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT)T Poynard, P Marcellin, S S Lee, et al.
Clinical and Experimental Rheumatology|January 1, 1991
Latent hepatitis B virus (HBV) infection in systemic necrotizing vasculitisP Marcellin, Y Calmus, H Takahashi, et al.
Journal of Hepatology|March 1, 1992
Failure of acyclovir to enhance the antiviral effect of alpha lymphoblastoid interferon on HBe-seroconversion in chronic hepatitis B. A multi-centre randomized controlled trialL Berk, S W Schalm, R A de Man, et al.
Hepatology (Baltimore, Md.)|October 27, 2001
Prospective study on anti-hepatitis C virus-positive patients with persistently normal serum alanine transaminase with or without detectable serum hepatitis C virus RNAM Martinot-Peignoux, N Boyer, D Cazals-Hatem, et al.
Transplantation|June 15, 1995
alpha-Interferon-induced rejection of a hepatitis C virus-infected liver allograft tolerated with a low dosage immunosuppressive regimenA C Gadano, J F Mosnier, F Durand, et al.
Journal of Viral Hepatitis|January 11, 2008
Hepatic steatosis in chronic hepatitis C: baseline host and viral characteristics and influence on response to therapy with peginterferon alpha-2a plus ribavirinK R Reddy, S Govindarajan, P Marcellin, et al.
Journal of Hepatology|March 9, 2000
A phase I/II study of recombinant human interleukin-12 in patients with chronic hepatitis BV Carreño, S Zeuzem, U Hopf, et al.
Pageof 22

Showing results (161-170 of 212) with videos related to

Sort By:
Pageof 22
Journal of Viral Hepatitis|September 24, 2016
No detectable resistance to tenofovir disoproxil fumarate in HBeAg+ and HBeAg- patients with chronic hepatitis B after 8 years of treatmentY Liu, A C Corsa, M Buti, et al.
Gut|September 27, 2007
Liver gene expression signature to predict response to pegylated interferon plus ribavirin combination therapy in patients with chronic hepatitis CT Asselah, I Bieche, S Narguet, et al.
Clinical and Experimental Immunology|November 1, 1995
CD4+/CD8+ ratio of liver-derived lymphocytes is related to viraemia and not to hepatitis C virus genotypes in chronic hepatitis CB N Pham, M Martinot-Peignoux, J F Mosnier, et al.
Lancet (London, England)|November 10, 1998
Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT)T Poynard, P Marcellin, S S Lee, et al.
Clinical and Experimental Rheumatology|January 1, 1991
Latent hepatitis B virus (HBV) infection in systemic necrotizing vasculitisP Marcellin, Y Calmus, H Takahashi, et al.
Journal of Hepatology|March 1, 1992
Failure of acyclovir to enhance the antiviral effect of alpha lymphoblastoid interferon on HBe-seroconversion in chronic hepatitis B. A multi-centre randomized controlled trialL Berk, S W Schalm, R A de Man, et al.
Hepatology (Baltimore, Md.)|October 27, 2001
Prospective study on anti-hepatitis C virus-positive patients with persistently normal serum alanine transaminase with or without detectable serum hepatitis C virus RNAM Martinot-Peignoux, N Boyer, D Cazals-Hatem, et al.
Transplantation|June 15, 1995
alpha-Interferon-induced rejection of a hepatitis C virus-infected liver allograft tolerated with a low dosage immunosuppressive regimenA C Gadano, J F Mosnier, F Durand, et al.
Journal of Viral Hepatitis|January 11, 2008
Hepatic steatosis in chronic hepatitis C: baseline host and viral characteristics and influence on response to therapy with peginterferon alpha-2a plus ribavirinK R Reddy, S Govindarajan, P Marcellin, et al.
Journal of Hepatology|March 9, 2000
A phase I/II study of recombinant human interleukin-12 in patients with chronic hepatitis BV Carreño, S Zeuzem, U Hopf, et al.
Pageof 22